HomeGeneticsGeneGNPTAB gene
Back to Gene
GNPTAB gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

GNPTAB gene

The GNPTAB gene is responsible for creating subunits of an enzyme that tags specific proteins for transport to lysosomes, the cell's recycling centers.

Normal Function

The GNPTAB gene provides instructions for making two parts—the alpha and beta subunits—of an enzyme called GlcNAc-1-phosphotransferase. This enzyme is composed of two alpha (α), two beta (β), and two gamma (γ) subunits (the gamma subunit is produced by the GNPTG gene). GlcNAc-1-phosphotransferase helps prepare certain newly made enzymes for transport to lysosomes, which are compartments within the cell that use digestive enzymes called hydrolases to break down large molecules for reuse.

The enzyme is involved in the first step of creating a molecule called mannose-6-phosphate (M6P). M6P acts as a tag that signals a hydrolase should be transported to the lysosome. Specifically, GlcNAc-1-phosphotransferase transfers a molecule called GlcNAc-1-phosphate to a newly produced hydrolase. In a subsequent step, a molecule is removed to reveal the M6P tag, allowing the hydrolase to be transported to the lysosome.

Health Conditions Related to Genetic Changes

Mucolipidosis II alpha/beta

Approximately 50 mutations in the GNPTAB gene have been identified as causes of mucolipidosis II alpha/beta. These mutations prevent the production of functional GlcNAc-1-phosphotransferase. Without this enzyme, hydrolases cannot be tagged with M6P and transported to lysosomes. Instead, these enzymes end up outside the cell, where they exhibit increased digestive activity. The resulting lack of hydrolases within lysosomes causes large molecules to accumulate, characterizing this as a lysosomal storage disorder.

Mucolipidosis III alpha/beta

Mutations in the GNPTAB gene can also cause mucolipidosis III alpha/beta. In these cases, mutations result in reduced activity of GlcNAc-1-phosphotransferase, which disrupts the tagging of hydrolases. Similar to mucolipidosis II, the shortage of these digestive enzymes within lysosomes leads to the accumulation of large molecules, classifying this condition as a lysosomal storage disorder.

Other Names for This Gene

  • alpha-beta GlcNAc-1-phosphotransferase
  • DKFZp762B226
  • GlcNAc phosphotransferase
  • GlcNAc-1-phosphotransferase
  • GNPTA
  • GNPTA_HUMAN
  • KIAA1208
  • MGC4170
  • N-acetylglucosamine-1-phosphate transferase
  • N-acetylglucosamine-1-phosphate transferase alpha and beta subunits
  • UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosamine
  • uridine 5'-diphosphate-N-acetylglucosamine: lysosomal hydrolase N-acetyl-1-phosphotransferase

Frequently Asked Questions

Key early clues are severe failure to thrive, joint contractures, thickened skin, and abnormal bone development visible on X‑ray (dysostosis multiplex). Persistent respiratory infections and feeding difficulties in the first year of life also raise suspicion.
Diagnosis begins with clinical evaluation (growth delay, skeletal abnormalities, coarse facial features) and laboratory studies showing elevated lysosomal enzymes in the blood. Confirmatory testing includes sequencing of the GNPTAB gene to identify pathogenic variants, often performed as part of a lysosomal storage disorder panel or whole‑exome sequencing.
Currently there is no cure; management focuses on supportive care—regular physiotherapy to maintain joint mobility, airway clearance techniques, nutritional support, and monitoring for cardiac or orthopedic complications. Hematopoietic stem cell transplantation has been explored but lacks consistent benefit.
GNPTAB mutations cause an autosomal recessive disorder. Both parents are typically carriers; each subsequent pregnancy has a 25 % chance of an affected child, a 50 % chance of a carrier, and a 25 % chance of an unaffected, non‑carrier child. Carrier testing and prenatal diagnosis are available.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA